
By Deena Beasley
SAN DIEGO Dec 2 (Reuters) - Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, acknowledging criticism that Novo's studies had design flaws.
Although the trials failed to show statistically significant slowing of cognitive decline in patients given the drug, "we still think it was the right decision... a scientific question that needed an answer," Peter Johannsen, Novo's international medical vice president, said in an address at the Clinical Trials in Alzheimer's Disease meeting in San Diego.
Data, now consolidated on Novo's website, had shown evidence that the GLP-1 hormone is involved in neurotransmission, with multiple effects across the brain, he said.
While Alzheimer's is defined by the presence of toxic amyloid plaques in the brain, "there are still things we don't know" about the pathology of the disease, Johannsen said. "This is a very complex disease with a lot of things going on with different genetic signatures."
Novo is slated to present on Wednesday initial results from the two 2-year studies that tested Novo's GLP-1 diabetes pill Rybelsus against a placebo in nearly 4,000 Alzheimer's patients.
Full results will be presented at a different medical meeting in March. The company issued a short press release last week saying the studies did not meet their goals.
COGNITIVE BENEFITS IN DIABETES PATIENTS
Johannsen said retrospective studies have shown cognitive benefits for diabetes patients using GLP-1s, which were first approved for blood-sugar control, with gains showing up after about a year of treatment, and building with longer-term use.
Some of those analyses did not specify which type of dementia a patient developed. Some of the real-world evidence was based on clinical diagnosis of Alzheimer's rather than more accurate testing and identification of amyloid plaques.
About 60% of people with dementia have Alzheimer's, according to the Alzheimer's Association, with the remaining cases caused by vascular or other issues.
Johannsen noted potential "biases" in real-world analyses. The diabetes patients prescribed GLP-1s likely had access to endocrinologists, rather than only primary care, and may be in higher socioeconomic groups than the general population, he said.
Patients on GLP-1s for diabetes probably have better glycemic and metabolic control than those not on the treatments, he said, possibly delaying them from seeking further help and being diagnosed with dementia.
(Reporting By Deena BeasleyEditing by Bill Berkrot)
latest_posts
- 1
IDF strikes Shiraz petrochemical site, releases footage of attacks on Iranian air defenses - 2
Changing Negative Cash Mentalities: Enabling Your Monetary Excursion - 3
FACT FOCUS: Trump sows confusion on number of childhood vaccinations - 4
NASA's Artemis astronauts enter final preparations for Moon mission - 5
State asks High Court to reject challenge to anti-UNRWA laws ahead of Monday hearing
The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
Instructions to Upgrade the Proficiency of Your Sunlight powered chargers
The Force of Care: Living with Goal
If you want a true taste of Italian paradise, head to Favignana
Step by step instructions to Get a good deal on Your Rooftop Substitution Venture
At least 30 killed in attack on Nigeria village
VPN Administrations for Online Protection
Toddler given just 3 years to live after strange symptoms makes full recovery
'You're no longer my sister' - rows erupt as war divides Iranian families













